KR930703445A - 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현 - Google Patents
톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현Info
- Publication number
- KR930703445A KR930703445A KR1019930701891A KR930701891A KR930703445A KR 930703445 A KR930703445 A KR 930703445A KR 1019930701891 A KR1019930701891 A KR 1019930701891A KR 930701891 A KR930701891 A KR 930701891A KR 930703445 A KR930703445 A KR 930703445A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- gondi
- antibody
- protein
- probe
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title claims abstract 17
- 108091007433 antigens Proteins 0.000 title claims abstract 17
- 241000223997 Toxoplasma gondii Species 0.000 title 1
- 238000010367 cloning Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 18
- 241001465754 Metazoa Species 0.000 claims abstract 7
- 208000015181 infectious disease Diseases 0.000 claims abstract 5
- 108020004414 DNA Proteins 0.000 claims abstract 4
- 229960005486 vaccine Drugs 0.000 claims abstract 3
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract 2
- 238000001514 detection method Methods 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000053602 DNA Human genes 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000001262 western blot Methods 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 201000005485 Toxoplasmosis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
숙주 세포내 한정된 티, 곤디 cDNA(제2도)의 발현에 의해 얻어진 재조합체 단백질에 대항하여 발생되고, 또한 단, 54-kDa 항원의 면역원성 단편인 항체와 반응성인, 분자량 54-kDa(웨스턴 블롯팅에 의해 결정됨)을 갖는 티, 곤디(T, gondii)의 정제 항원이 제공된다. 또한 54-kDa 항원을 암호하는 제조합체 DNA, 그러한 DNA의 발현을 위한 숙주 세포, 사람 및 동물에 있어서 톡소플라스마병 감염 치료 또는 예방을 위한 백신 및 티, 곤디 항원 또는 항체의 검출을 위한 시험 키트가 기술된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 Tg 34로서 공지된 cDNA 분지계를 위한 서열화 전략을 제시한다. 제2도는 Tg 34 cDNA 분지계의 뉴클레오티드 및 추론된 아미노산 서열을 제시한다.
Claims (15)
- (a) 제2도에 제시된 서열에 의해 나타내어진 DNA 서열의 적어도 일부, (b) 상기 서열에 대한 유전암호의 결과로서 변성되는 DNA 서열, 또는 (c) 상기 서열의 상보적인 서열에 대해 엄격한 조건 하에서 혼성체화하는 DNA 서열을 포함하며, (i) 티, 곤디(T, gondii)로 감염된 사람 및 동물의 혈청 또는 그 밖의 생물학적 시료에서 항원에 의해 인식될 수 있으나, (ii) 사람 또는 동물에게 내부 투여한 후 항체를 발생시킬 수 있는 단백질을 암호하는 제조합체 DNA 분자.
- 제1항에 청구된 DNA 분자의 상보적 서열을 포함하는 제조합체 DNA 분자.
- 제1항 또는 제2항에 따른 DNA를 포함하는 재조합체 백터.
- 제3항에 있어서, 웨스턴 블롯팅에 의해 결정되나 크기가 대략 54-kDa인티,곤디의 항원을 암호하는 재조합체 벡터.
- 제3항 또는 제4항에 따른 벡터에 의해 형질전환된 숙주 세포.
- 제2도에 제시된 아미노산 서열의 적어도 일부를 포함하는, (i)티,곤디로 감염된 사람 및 동물의 혈청 또는 그 밖의 생물학적 시료에서 항체에 의해 인식될 수 있으나, (ii) 사람 또는 동물에게 내부 투여한 후에 항체를 발생시킬 수 있는 정제 단백질.
- 제6항에 있어서, 웨스턴 블롯팅에 의해 결정되나 크기가 대략 54-kDa인 단백질.
- 제약학적으로 허영가능한 부형제와 함께 제6항 또는 제7항에서 청구되는 바와 단백질 면연 보호량을 포함하는티,곤디감염에 대항하는 백신 조성물.
- (a) 프로브 항원으로서 제6항 또는 제7항에 따른 단백질과 항-티,곤디항체를 함유할 것이라 생각되는 시료의 항온처리, 및 (b) 프로브 항원을 함유하는 항체-항원 복합체의 검출로 구성된티,곤디항원에 대항하는 항체를 검출하는 방법.
- (a) 프로브 항원으로서 제6항 또는 제7항에 따른 단백질, (b) 프로브 항원을 함유하는 항체-항원 복합체의 검출하기 위한 수단을 포함하는티,곤디에 의해 감염되기 쉬운 사람 또는 동물에 있어서, 항체를 검출을 위한 시험 키트.
- 제6항 또는 제7항에 따른 단백질의 에피토프에 대항하는 단일분지계 항체.
- 제11항에 있어서, 치료에 사용하기 위한 단일분지계 항체.
- (a) 프로브 항원으로서 제12항에 따른 단일 분지계 항체, 및 (b) 프로브 항체를 함유하는 항원-항체 복합체를 검출하기 위한 수단을 포함하는,티,곤디항원을 함유할 것이라 생각되는 시료에서 상기 항원을 검출하기 위한 시험 키트.
- 티,곤디항원의 발현을 허락하는 조건하 제5항에 따른 숙주 세포를 항온처리하는 것을 포함하는티,곤디항원을 생산하는 방법.
- 티,곤디감염의 예방 또는 치료를 필요로 하는 사람 또는 동물에게 유효량의 제8항에 따른 백신 조성물을 투여하는 것을 포함하는, 사람 또는 동물에 있어서티,곤디감염을 치료 또는 예방하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909027728A GB9027728D0 (en) | 1990-12-20 | 1990-12-20 | Novel protein |
| GB9027728.6 | 1990-12-20 | ||
| PCT/EP1991/002423 WO1992011366A1 (en) | 1990-12-20 | 1991-12-16 | Cloning and expression of a protein antigen of toxoplasma gondii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930703445A true KR930703445A (ko) | 1993-11-30 |
| KR100250944B1 KR100250944B1 (ko) | 2000-04-15 |
Family
ID=10687389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930701891A KR100250944B1 (ko) | 1990-12-20 | 1991-12-16 | 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현 |
| KR1019997010057A KR100260998B1 (en) | 1990-12-20 | 1999-10-29 | A protein antigen of toxoplasma gondii |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019997010057A KR100260998B1 (en) | 1990-12-20 | 1999-10-29 | A protein antigen of toxoplasma gondii |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6077690A (ko) |
| EP (1) | EP0652956A1 (ko) |
| JP (1) | JPH06505865A (ko) |
| KR (2) | KR100250944B1 (ko) |
| AU (1) | AU661982B2 (ko) |
| CA (1) | CA2098845A1 (ko) |
| GB (1) | GB9027728D0 (ko) |
| IE (1) | IE914422A1 (ko) |
| MX (1) | MX9102647A (ko) |
| NZ (1) | NZ241043A (ko) |
| PT (1) | PT99842A (ko) |
| SG (1) | SG48325A1 (ko) |
| WO (1) | WO1992011366A1 (ko) |
| ZA (1) | ZA919982B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
| JPH08512200A (ja) * | 1993-04-30 | 1996-12-24 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | クローニング、発現およびトキソプラズマ・ゴンヂのペプチド抗原に対応するワクチン組成物 |
| ZA958366B (en) * | 1994-10-06 | 1996-04-24 | Akzo Nobel Nv | New toxoplasma gondii antigens |
| GB9929434D0 (en) * | 1999-12-13 | 2000-02-09 | Smithkline Beecham Biolog | Novel vaccine composition |
| WO2002017960A1 (en) * | 2000-08-31 | 2002-03-07 | Chugai Seiyaku Kabushiki Kaisha | Vaccines against toxoplasma gondii |
| CA2599620A1 (en) | 2005-03-08 | 2006-09-14 | Kenton Srl | Chimeric recombinant antigens of toxoplasma gondii |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3940598A1 (de) * | 1989-12-08 | 1991-06-13 | Behringwerke Ag | Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung |
| US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| FR2618680B1 (fr) * | 1987-07-31 | 1990-05-11 | Pasteur Institut | Antigenes d'excretion-secretion specifiques de toxoplasma gondii, leurs produits d'expression, leur procede d'obtention et leurs applications diagnostiques et prophylactiques |
| US4877726A (en) * | 1988-03-02 | 1989-10-31 | Research Institute Of Palo Alto Medical Foundation | Method for the detection of acute-phase toxoplasma infection |
| IL93883A (en) * | 1989-04-12 | 1993-02-21 | Iscar Ltd | Cutting insert for a milling cutting tool |
-
1990
- 1990-12-20 GB GB909027728A patent/GB9027728D0/en active Pending
-
1991
- 1991-11-06 ZA ZA919982A patent/ZA919982B/xx unknown
- 1991-12-16 KR KR1019930701891A patent/KR100250944B1/ko not_active IP Right Cessation
- 1991-12-16 SG SG1996008928A patent/SG48325A1/en unknown
- 1991-12-16 WO PCT/EP1991/002423 patent/WO1992011366A1/en not_active Application Discontinuation
- 1991-12-16 JP JP4501657A patent/JPH06505865A/ja active Pending
- 1991-12-16 CA CA002098845A patent/CA2098845A1/en not_active Abandoned
- 1991-12-16 AU AU90714/91A patent/AU661982B2/en not_active Expired
- 1991-12-16 EP EP92901011A patent/EP0652956A1/en not_active Withdrawn
- 1991-12-18 NZ NZ241043A patent/NZ241043A/xx not_active IP Right Cessation
- 1991-12-18 PT PT99842A patent/PT99842A/pt not_active Application Discontinuation
- 1991-12-18 MX MX9102647A patent/MX9102647A/es unknown
- 1991-12-18 IE IE442291A patent/IE914422A1/en not_active Application Discontinuation
-
1995
- 1995-06-02 US US08/458,922 patent/US6077690A/en not_active Expired - Lifetime
-
1999
- 1999-10-29 KR KR1019997010057A patent/KR100260998B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100250944B1 (ko) | 2000-04-15 |
| MX9102647A (es) | 1994-03-31 |
| GB9027728D0 (en) | 1991-02-13 |
| US6077690A (en) | 2000-06-20 |
| JPH06505865A (ja) | 1994-07-07 |
| KR100260998B1 (en) | 2000-06-15 |
| EP0652956A1 (en) | 1995-05-17 |
| NZ241043A (en) | 1993-09-27 |
| WO1992011366A1 (en) | 1992-07-09 |
| AU9071491A (en) | 1992-07-22 |
| PT99842A (pt) | 1992-12-31 |
| CA2098845A1 (en) | 1992-06-21 |
| IE914422A1 (en) | 1992-07-01 |
| AU661982B2 (en) | 1995-08-17 |
| SG48325A1 (en) | 1998-04-17 |
| ZA919982B (en) | 1992-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parks et al. | Radioimmunoassay of mammalian type-C viral proteins: interspecies antigenic reactivities of the major internal polypeptide | |
| CA1194794A (en) | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom | |
| JP2573815B2 (ja) | マイコバクテリウム感染検出合成ポリペプチド | |
| Oppermann et al. | A joint product of the genes gag and pol of avian sarcoma virus: a possible precursor of reverse transcriptase | |
| Handman et al. | Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies | |
| Lewis et al. | C-type viruses in systemic lupus erythematosus | |
| RU2003104976A (ru) | Соединения и способ для лечения и диагностики хламидийной инфекции | |
| KR910000183A (ko) | 재조합 포자충증 백신 | |
| JPH0678359B2 (ja) | エプスタイン、バールウィルス核抗原と免疫反応する抗体を産生する化学的に合成されたポリペプチド | |
| Harn et al. | Schistosoma mansoni: detection by monoclonal antibody of a 22,000-dalton surface membrane antigen which may be blocked by host molecules on lung stage parasites. | |
| Fagraeus et al. | Anti-actin antibodies | |
| Michael et al. | All eight unassigned reading frames of mouse mitochondrial DNA are expressed. | |
| Teramoto et al. | Type-specific antigenic determinants on the major external glycoprotein of high-and low-oncogenic murine mammary tumor viruses | |
| Noon et al. | Expression of mouse mammary tumor viral polypeptides in milks and tissues | |
| KR930703445A (ko) | 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현 | |
| Trainin et al. | IgG and IgM antibodies in normal and leukaemic cattle | |
| JPS60155133A (ja) | アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン | |
| Versteegen et al. | Effect of chemical modification and fragmentation on antigenic determinants of internal protein p30 and surface glycoprotein gp70 of type C retroviruses | |
| Stahmann et al. | Immunochemistry of Synthetic Polypeptides and Polypeptidyl Proteins: I. Qualitative Studies on the Modified Proteins | |
| Vora et al. | Production and characterization of monoclonal antibodies to the subunits of human phosphofructokinase: new tools for the immunochemical and genetic analyses of isozymes | |
| Yamada et al. | Suppression of natural killer cell activity by chicken α-fetoprotein in Japanese quails | |
| Von Mühlen et al. | Non‐muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus‐associated chronic liver diseases | |
| Fritz et al. | Specificity of antisera from Lewis rats immunized with encephalitogenic fragment 43–88 of guinea pig myelin basic protein | |
| Natraj et al. | Termination of pregnancy in mice following administration of antibodies to the pentadecapeptide 10–24 of chicken riboflavin carrier protein: Identification of a bioneutralizing epitope of chicken riboflavin carrier protein | |
| Barbet et al. | Cross reacting determinants in trypanosome surface antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| A107 | Divisional application of patent | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20101229 Year of fee payment: 12 |
|
| EXPY | Expiration of term |